Screener
Boston Scientific BSX Interventional Cardiology & Vascular Therapies — Net Sales
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Boston Scientific in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Boston Scientific’s 10-K, filed February 17, 2026.
- Filed
- Feb 17, 2026, 4:08 PM EST
- Fiscal year
- FY2025
- Accession
- 0000885725-26-000010
| Businesses | Year Ended December 31, 2025 / U.S. | Year Ended December 31, 2025 / Int'l | Year Ended December 31, 2025 / Total | Year Ended December 31, 2024 / U.S. | Year Ended December 31, 2024 / Int'l | Year Ended December 31, 2024 / Total | Year Ended December 31, 2023 / U.S. | Year Ended December 31, 2023 / Int'l | Year Ended December 31, 2023 / Total |
|---|---|---|---|---|---|---|---|---|---|
| Urology | 2,000 | 709 | 2,709 | 1,557 | 643 | 2,200 | 1,369 | 595 | 1,964 |
| Neuromodulation | 914 | 285 | 1,199 | 847 | 259 | 1,106 | 736 | 240 | 976 |
| MedSurg | 4,715 | 2,108 | 6,824 | 4,054 | 1,939 | 5,993 | 3,617 | 1,805 | 5,422 |
| Interventional Cardiology & Vascular Therapies | 2,007 | 2,632 | 4,639 | 1,607 | 2,592 | 4,199 | 1,436 | 2,355 | 3,791 |
| Watchman | 1,791 | 167 | 1,958 | 1,371 | 145 | 1,516 | 1,155 | 119 | 1,274 |
| Electrophysiology | 2,311 | 1,014 | 3,325 | 1,256 | 648 | 1,904 | 370 | 430 | 800 |
| Cardiac Rhythm Management | 1,425 | 907 | 2,332 | 1,403 | 876 | 2,279 | 1,405 | 813 | 2,218 |
| Interventional Oncology & Embolization | 615 | 381 | 996 | 518 | 338 | 856 | 442 | 294 | 736 |
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
FAQ
- What is Boston Scientific's interventional cardiology & vascular therapies — net sales?
- Boston Scientific (BSX) reported interventional cardiology & vascular therapies — net sales of $1.16B in Q4 2025.
- How has Boston Scientific's interventional cardiology & vascular therapies — net sales changed year-over-year?
- Boston Scientific's interventional cardiology & vascular therapies — net sales increased by 10.5% year-over-year, from $1.05B to $1.16B.
- What is the long-term trend for Boston Scientific's interventional cardiology & vascular therapies — net sales?
- Over 2 years (2023 to 2025), Boston Scientific's interventional cardiology & vascular therapies — net sales has grown at a 10.6% compound annual growth rate (CAGR), from $3.79B to $4.64B.
- What does interventional cardiology & vascular therapies — net sales mean?
- This metric represents the total revenue generated from the sale of medical devices and technologies specifically designed for interventional cardiology and vascular procedures. It captures the financial performance of products used in minimally invasive treatments for heart and vascular conditions, reflecting the company's market penetration and demand for its specialized therapeutic portfolio. This revenue stream is a primary indicator of the segment's ability to capture market share in the high-growth cardiovascular medical device sector.
Ask your AI about Boston Scientific's interventional cardiology & vascular therapies — net sales.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude